News Headlines

  1. Merck Animal Health And State Of Kansas Announce $895M Investment In Manufacturing And Research & Development Facilities In De Soto 5/8/2025

    Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, and Kansas Governor Laura Kelly jointly announced today the $895M expansion of Merck Animal Health’s manufacturing facility in De Soto, Kansas.

  2. VintaBio Unveils New Data Showcasing Scalable AAV Perfusion Manufacturing Platform With High Full Capsid Yield At 2025 ASGCT Annual Meeting 5/8/2025

    VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present transformative data on its proprietary VintaProcess™, an advanced intensified adherent viral vector manufacturing platform.

  3. Ratio Therapeutics To Establish New Radiopharmaceutical Manufacturing Facility 5/8/2025

    Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced that it entered into an agreement with the Medical Innovation Technology Management division of Wasatch Group to partner and construct a state-of-the-art radiopharmaceutical research and manufacturing facility in Salt Lake City, Utah, anticipated to be fully operational in the second half of 2027.

  4. Colorcon And ASHA Cellulose Announce New Partnership To Support The Development & Manufacture Of Barrier Membrane Formulations For The Pharmaceutical And Nutraceutical Industries 5/8/2025

    Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere packaging for the healthcare industry, today announced an exclusive partnership with ASHA Cellulose, a leading provider of organo-soluble Ethyl cellulose polymers widely used in the pharmaceutical and dietary supplement industries.

  5. Cellipont Bioservices And Optieum Biotechnologies Partner To Advance cGMP Manufacturing Of Groundbreaking CAR-T Therapy For Glioblastoma 5/8/2025

    Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies (Optieum), a preclinical stage company dedicated to the discovery and development of innovative Chimeric Antigen Receptor (CAR) T cell therapies, today announced a partnership for cGMP manufacturing of OPTF01, Optieum's novel CAR-T therapy for glioblastoma treatment, a product derived from their proprietary Eumbody System.

  6. NewBiologix Licenses Xcell-Eng-HEK293 Cell Line To ReciBioPharm For Development And Manufacture Of Adeno-Associated Virus (AAV) Therapeutics 5/8/2025

    NewBiologix, a technology innovation company enabling efficient, cost-effective, and scalable production of viral vectors for cell and gene therapy (C>), today announced it has granted a non-exclusive technology license to ReciBioPharm – Recipharm’s Advanced Therapies (ATMP) division and a leading Contract Development and Manufacturing Organization (CDMO) – to provide global biotech and pharma companies with access to NewBiologix’s Xcell-Eng-HEK293 cell lines.

  7. Minaris Advanced Therapies Launches As The Leading Global Partner Dedicated To Cell Therapy Development, Manufacturing, And Testing 5/7/2025

    Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi Advanced Therapies have been combined to form Minaris Advanced Therapies, a global cell therapy CDMO and testing partner.

  8. Univercells Technologies Debuts The Scale-X Nitro Controller To Expand Access To Large-Scale Viral And Advanced Therapy Manufacturing 5/7/2025

    Univercells Technologies, a Donaldson Life Sciences business and global provider of bioprocessing solutions, announced the launch of the scale-X nitro controller, the latest addition to its scale-X fixed-bed bioreactor portfolio.

  9. Neurosense Therapeutics Announces Successful Completion Of Commercial Manufacturing Scale-Up For PrimeC In Preparation For Potential Canadian Market Launch 5/7/2025

    NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it has successfully scaled-up its production of PrimeC to commercial scale, marking a significant step toward bringing this potential disease-modifying ALS therapy to patients, following the promising efficacy data demonstrated in the Phase 2b PARADIGM study.

  10. GeneFab And RegCell Announce Strategic Partnership To Advance Autoimmune Cell Therapy Into U.S. Clinical Trials 5/7/2025

    GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCell, a biotech company advancing regulatory T cell (Treg) therapies for autoimmune diseases.